JP2009506002A5 - - Google Patents

Download PDF

Info

Publication number
JP2009506002A5
JP2009506002A5 JP2008527426A JP2008527426A JP2009506002A5 JP 2009506002 A5 JP2009506002 A5 JP 2009506002A5 JP 2008527426 A JP2008527426 A JP 2008527426A JP 2008527426 A JP2008527426 A JP 2008527426A JP 2009506002 A5 JP2009506002 A5 JP 2009506002A5
Authority
JP
Japan
Prior art keywords
ambroxol
acceptable salt
liquid
use according
dosage form
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008527426A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009506002A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2006/064999 external-priority patent/WO2007023072A2/en
Publication of JP2009506002A publication Critical patent/JP2009506002A/ja
Publication of JP2009506002A5 publication Critical patent/JP2009506002A5/ja
Pending legal-status Critical Current

Links

JP2008527426A 2005-08-25 2006-08-03 ライノウィルスの感染症治療の為のアンブロキソールの使用 Pending JP2009506002A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05107792 2005-08-25
PCT/EP2006/064999 WO2007023072A2 (en) 2005-08-25 2006-08-03 Use of ambroxol for the treatment of rhinovirus infections

Publications (2)

Publication Number Publication Date
JP2009506002A JP2009506002A (ja) 2009-02-12
JP2009506002A5 true JP2009506002A5 (enExample) 2009-09-17

Family

ID=35519889

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008527426A Pending JP2009506002A (ja) 2005-08-25 2006-08-03 ライノウィルスの感染症治療の為のアンブロキソールの使用

Country Status (8)

Country Link
US (1) US20080319087A1 (enExample)
EP (1) EP1928444A2 (enExample)
JP (1) JP2009506002A (enExample)
BR (1) BRPI0614887A2 (enExample)
CA (1) CA2619863A1 (enExample)
MX (1) MX2008002456A (enExample)
RU (1) RU2409356C2 (enExample)
WO (1) WO2007023072A2 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012123466A1 (de) * 2011-03-14 2012-09-20 Boehringer Ingelheim International Gmbh Verwendung einer sprühfähigen zusammensetzung enthaltend ambroxol
KR101915056B1 (ko) 2012-04-10 2018-11-07 한미약품 주식회사 암브록솔, 레보드로프로피진 및 완충제를 포함하는 경구용 액상 제제 및 이의 제조방법
CN104606170A (zh) * 2015-02-04 2015-05-13 上海华源安徽仁济制药有限公司 一种盐酸氨溴索胶囊及其制备方法
CN105078896A (zh) * 2015-09-22 2015-11-25 青岛华之草医药科技有限公司 一种治疗咳嗽的药物盐酸氨溴索组合物干混悬剂
RU2701737C1 (ru) * 2018-06-28 2019-10-01 федеральное государственное бюджетное учреждение "Национальный исследовательский центр эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи" Министерства здравоохранения Российской Федерации Лекарственное средство для терапии хронических ран
IT201800006909A1 (it) * 2018-07-04 2020-01-04 Polvere secca di ambroxolo per uso inalatorio con target bronchiale
US11013687B1 (en) * 2020-06-08 2021-05-25 Amcyte Pharma, Inc. Preventive and therapeutic treatment for COVID 19 and any other disease caused by SARS CoV 2
WO2021255129A1 (en) * 2020-06-16 2021-12-23 Spedding Research Solutions, Sas Novel use of a modulator of glucosylceramide degradation for viral infections
EP4196154A4 (en) 2020-08-13 2025-01-22 Texas Southern University COMPOSITIONS AND METHODS FOR INHIBITING SARS-COV-2 INFECTION

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3610997A1 (de) * 1986-04-02 1987-10-15 Krewel Werke Gmbh Ambroxol-nasenspray
KR20040045429A (ko) * 2001-09-04 2004-06-01 베링거 인겔하임 인터내셔날 게엠베하 항인플루엔자 약제
US20050075403A1 (en) * 2003-10-02 2005-04-07 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ambroxol for the treatment of inflammation in the pharynx

Similar Documents

Publication Publication Date Title
JP2022180461A5 (enExample)
TWI496594B (zh) 噴灑用凝膠型皮膚及/或黏膜附著型製劑及使用該製劑之投藥系統
JP2009102342A5 (enExample)
JP2005515966A5 (enExample)
JP2014516942A5 (enExample)
JP2009522289A5 (enExample)
TW201016209A (en) Intranasal compositions, dosage forms and methods of treatments
KR20230027150A (ko) 코로나바이러스 감염 치료용 화합물
JP2008543936A5 (enExample)
EA022840B1 (ru) Фармацевтическая композиция, набор, их применение и способ профилактики и лечения симптома, состояния или заболевания, связанного с инфекцией вируса гриппа
JP2009506002A5 (enExample)
JP2019536812A5 (enExample)
JP2010524882A5 (enExample)
KR20230038228A (ko) 글루코코르티코이드 절약제
JP2019218379A5 (enExample)
JP2005500298A5 (enExample)
JP2012505830A5 (enExample)
ES2291618T3 (es) Composicion farmaceutica a base de un agente inhibidor de la pde4 o de la pde3/4 y de un agente antagonista de receptores de histamina.
RU2013119595A (ru) Низкодозовая фармацевтическая композиция
RU2008110933A (ru) Применение амброксола для лечения риновирусных инфекций
ES2309357T3 (es) Nueva combinacion sinergica que comprende roflumilast y formoterol.
US20240075029A1 (en) Luminol for the prophylaxis and the treatment of sequelae of a sars-cov-2 infection
FI3934653T3 (fi) Atselastiini antiviraalisessa hoidossa
CN115551515A (zh) 靶向3CLpro的连翘苷及其衍生物和抗新冠应用
CN119700755A (zh) 化合物在制备预防和/或治疗高原病的药物中的应用